{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T04:50:52Z","timestamp":1767156652630,"version":"build-2065373602"},"reference-count":8,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013116","name":"Merz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013116","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Otolaryngology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.amjoto.2022.103613","type":"journal-article","created":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T19:01:34Z","timestamp":1661626894000},"page":"103613","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["IncobotulinimtoxinA (Xeomin) for the treatment of adductor laryngeal dystonia: A prospective, open-label clinical trial"],"prefix":"10.1016","volume":"43","author":[{"given":"Nikita","family":"Kohli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Lerner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Rashty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Kirke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Blitzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.amjoto.2022.103613_bb0005","first-page":"S1","article-title":"Phenomenology, genetics and CNS network abnormalities in laryngeal dystonia: a 30-year experience","volume":"128","author":"Blitzer","year":"2018","journal-title":"Laryngoscope"},{"issue":"7","key":"10.1016\/j.amjoto.2022.103613_bb0010","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1212\/01.WNL.0000055087.96356.BB","article-title":"Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia","volume":"60","author":"Jankovic","year":"2003","journal-title":"J Neurology"},{"issue":"7","key":"10.1016\/j.amjoto.2022.103613_bb0015","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.imbio.2010.12.009","article-title":"Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies","volume":"216","author":"Atassi","year":"2011","journal-title":"Immunobiology"},{"issue":"4","key":"10.1016\/j.amjoto.2022.103613_bb0020","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/jocd.12108","article-title":"Clinical resistance to three types of botulinum toxin type A in aesthetic medicine","volume":"13","author":"Stephan","year":"2014","journal-title":"J Cosmetic Dermatology"},{"issue":"10","key":"10.1016\/j.amjoto.2022.103613_bb0025","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/mds.22157","article-title":"Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. BonTA Study Group","volume":"23","author":"Brin","year":"2008","journal-title":"Movement Disorders"},{"issue":"9","key":"10.1016\/j.amjoto.2022.103613_bb0030","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1097\/00005537-200409000-00009","article-title":"Development and validation of the voice handicap index 10","volume":"114","author":"Rosen","year":"2004","journal-title":"Laryngoscope"},{"key":"10.1016\/j.amjoto.2022.103613_bb0035","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/lary.21395","article-title":"Botulinum toxin treatment of adductor spasmodic dysphonia: longitudinal functional outcomes","volume":"121","author":"Novakovic","year":"2011","journal-title":"Laryngoscope"},{"issue":"4","key":"10.1016\/j.amjoto.2022.103613_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjopen-2011-000646","article-title":"Prospective analysis of neutralising antibody titres in secondary non-responders under continuous treatment with a botulinumtoxin type A preparation free of complexing proteins\u2014a single cohort 4-year follow-up study","volume":"2","author":"Hefter","year":"2012","journal-title":"BMJ Open"}],"container-title":["American Journal of Otolaryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019607092200240X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019607092200240X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T05:09:00Z","timestamp":1759295340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019607092200240X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S019607092200240X"],"URL":"https:\/\/doi.org\/10.1016\/j.amjoto.2022.103613","relation":{},"ISSN":["0196-0709"],"issn-type":[{"type":"print","value":"0196-0709"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IncobotulinimtoxinA (Xeomin) for the treatment of adductor laryngeal dystonia: A prospective, open-label clinical trial","name":"articletitle","label":"Article Title"},{"value":"American Journal of Otolaryngology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjoto.2022.103613","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103613"}}